Skip to content
FIND A HEALTH VALLEY ACTOR

Lonza completed its latest drug manufacturing line in Visp

Ibex™ Lonza facilit in Visp Switzerland

The new line will support customers with a range of drug product manufacturing needs for both clinical and commercial supply.   Set in a 1,200 sqm cGMP facility, it includes a state-of-the-art liquid and lyophilized vial filling isolator line for multiple modalities that fulfils the GMP Annex 1 requirement for the manufacture of sterile products1.…

Read More

W.A. de Vigier Awards 2023: 7 Western Switzerland Life Sciences Startups Selected

De Vigier Awards

15 startups were selected among 300 projects. 5 of them are set to win CHF 100,000. The Award Ceremony is scheduled on 20 June 2023.   The Top 15 will now be further assessed through in-depth interviews with the foundation board as well as expert reports. The Top 10 are subsequently selected during two presentation…

Read More

An Obesity Center opens at the CHUV

Obesity Center CHUV

The creation of an Obesity Center at the CHUV enables the teams of Dr. Lucie Favre, head of the Obesity Consultation (Endocrinology Service), and Dr. Styliani Mantziari, head of the Bariatric Surgery Unit (Visceral Surgery Service), to combine their expertise in order to offer multidisciplinary and personalized care to patients who suffer from obesity.  …

Read More

Alithea Genomics receives CHF 500,000 from FIT

Alithea Genomics

The EPFL spin-off is active in high-throughput RNA sequencing, used to examine gene expression and discover new biomarkers and drugs. The Foundation for Technological Innovation (FIT) has chosen to give the company a Tech Growth loan of CHF 500,000.     Since the Covide-19 pandemic, RNA sequencing is widely used in for fundamental research studies,…

Read More

Lunaphore raises CHF 40 million in Series D1 funding

Lunaphore

The Swiss startup plans to use the funding to strengthen its growing portfolio offering in spatial biology.     Lunaphore Technologies S.A is a Vaud-based spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research. The startup announced that it has completed CHF 40M in Series D1 funding. The round was…

Read More

A VR training programme for medical students supported by Innosuisse

OramaVR

Viva VOsCE is a revolutionary project aiming at transforming medical education through harnessing the power of Virtual Reality (VR) technology.   The project is being conducted in partnership with the Geneva University Hospitals (HUG) and the University of Bern, with ORamaVR S.A. as implementation partner. Objective Structured Clinical Examinations (OSCE) are critical for the practical…

Read More

Three new projects financed in Geneva by the FIF

FIF 2023

Plair, Endotelix and Dr Beat Walpoth received funding from the Fongit Innovation Fund (FIF).   Plair SA: Growth loan of 300’000 CHF This spin-off from the University of Geneva specializes in the development, manufacturing and marketing of professional systems for preventive environmental monitoring, using a proprietary state-of-the-art technology that forms the basis of its smart…

Read More

Senbiosys raises more than CHF 600,000 on kickstarter

Senbiosys

Senbiosys developed a smart ring and an application to give users inputs about their health and wellness. The EPFL spin-off raised CHF 622 672 on a Kickstarter crowdfunding campaign with more than 3465 backers. The company initially requested CHF 100,000 in funding.   A smart and elegant ring to monitor your health. Iris by Senbiosys…

Read More

Tech4Eva selected 16 projects for its 2023 programme

Tech4Eva 2023

16 projects have been selected for the 2023 programme   Tech4Eva is an EPFL Innovation Park and Groupe Mutuel initiative that aims at creating a long-term impact for FemTech startups and a global FemTech Community. The 2023 international cohort was selected from a total of 147 applications from 40 countries. Since the start of the…

Read More

Debiopharm and Merck invest in artificial intelligence

Debiopharm Innovation Fund

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and M Ventures, the strategic, corporate venture capital arm of Merck, and Omnes Capital invested CHF 15.5 million in French startup Iktos     By 2025, one in two drugs is expected to be discovered and developed using artificial intelligence. Iktos is a French…

Read More